Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

키워드

참고문헌 (15)

1. Shih CI, "Severity of fatty liver is highly correlated with the risk of hypertension and diabetes : a cross-sectional and longitudinal cohort study", Hepatol Int, 18, pp.138~154 (2024)
2. Kuo CS, "The impact of chronic hepatitis B infection on major adverse cardiovascular events and all-cause mortality in patients with diabetes : a nationwide population-based study from Taiwan", BMJ Open, 7, pp.e016179~ (2017)
3. Wu VC, "Comparison of cardiovascular outcomes and all-cause mortality in patients with chronic hepatitis B and C : A 13-year nationwide population-based study in Asia", Atherosclerosis, 269, pp.178~184 (2018)
4. Yun B, "Comparable mortality between Asian patients with chronic hepatitis B under longterm antiviral therapy vs matched control : A population-based study", Am J Gastroenterol, 118, pp.1001~1009 (2023)
5. Hong H, "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide", Clin Mol Hepatol, 30, pp.49~63 (2024)
6. Jeong J, "Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients : A propensity score-matched analysis", Clin Mol Hepatol, 28, pp.254~264 (2022)
7. Cheng PN, "Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B", Aliment Pharmacol Ther, 59, pp.230~238 (2024)
8. Lai RM, "Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients", World J Hepatol, 15, pp.964~972 (2023)
9. Giacomelli A, "Impact of switching to TAF", FTC, FTC, pp.EVG, cobi and ABC[DOI]
10. Chan HLY, "Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety", Am J Gastroenterol, 119, pp.486~496 (2023)
11. Hajar R, "Framingham contribution to cardiovascular disease", Heart Views, 17, pp.78~81 (2016)
12. Peleg N, "Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load", JHEP Rep, 1, pp.9~16 (2019)
13. Cheng PN, "Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases", Clin Mol Hepatol, 30, pp.16~36 (2024)
14. Choi HSJ, "Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B", Hepatology, 71, pp.539~548 (2020)
15. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)

관련 논문AI추천